Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Radium-223 chloride - Bayer HealthCare

Drug Profile

Radium-223 chloride - Bayer HealthCare

Alternative Names: AC1O4D1M; Alpharadin; ATI-BC-1; BAY88-8223; Radium Ra 233 dichloride; Radium-223; Radium-223 dichloride; Xofigo

Latest Information Update: 07 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Algeta
  • Developer Algeta; Bayer HealthCare; Janssen; Medica Scientia Innovation Research; Royal Marsden NHS Foundation Trust; Sheffield Teaching Hospitals NHS Foundation Trust; The Institute of Cancer Research; Thomas Jefferson University; University of Texas M. D. Anderson Cancer Center; University of Utah
  • Class Antineoplastics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bone metastases
  • Phase III Prostate cancer
  • Phase I/II Multiple myeloma
  • No development reported Osteosarcoma
  • Discontinued Cancer pain

Most Recent Events

  • 01 Dec 2018 Bayer and The Royal Marsden NHS Foundation Trust completes the REASURE phase II trial in Bone metastases (In adults, In adolescents, In the elderly) in United Kingdom (IV) (EudraCT2013-004055-20)
  • 13 Nov 2018 Brown University, Rhode Island Hospital, The Miriam Hospital and Bayer complete the phase II BrUOG L301 trial in Bone metastases (non-small cell lung cancer patients) in USA (NCT02283749)
  • 19 Oct 2018 Efficacy and safety data from an early access program in Prostate cancer presented at the 43rd European Society for Medical Oncology Congress (ESMO-2018) (NCT01618370)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top